Subscribe to Search results

Dr Dempsey understood there was still a risk of non-A non-B Hepatitis from commercial concentrates, but there was also a risk from NHS concentrates. He acknowledged that the risk with cryoprecipitate was "very much reduced risk."

Published on:

Dr Dempsey described batch dedication as "extremely difficult" and as something that ultimately did not work.

Published on:

Dr Dempsey had gathered from reading UKHCDO minutes that things had improved considerably in relation to the safety of commercial concentrates.

Published on:

Dr Dempsey recalled that the pharmaceutical firms, mostly Armour, were "keen to emphasise the fact that they'd tightened up on the type of donor they looked to for their plasma source" and reassured him that he was "disposed to look favourably on commercial concentrates at that point in time."

Published on:

Children at the RBHSC with moderate haemophilia were treated with these commercial concentrates; children with mild haemophilia were treated with DDAVP and tranexamic acid.

Published on:

Dr Dempsey's patients who would have been treated with commercial concentrates and SNBTS concentrates - were infected with Hepatitis C.

Published on:

Dr Dempsey was not aware, that BPL was producing a product at this time (8Y) which did not transmit hepatitis; had he known about it, he would have phoned BPL and requested a supply.

Published on:

Dr Dempsey continued to use SNBTS concentrates until he became aware of the infection of patients in Edinburgh. He used the heat-treated product NY until July 1987 when the next generation product Z8 became available. He was aware that non-A non-B Hepatitis could still be transmitted by NY.

Published on:

Dr Dempsey would not have used concentrate at all "given what was likely - or what was going to happen further down the road." The NHS product might have been a "better modality of treatment" to have employed back in 1981.

Published on:

Dr Winter told the Penrose Inquiry that by December 1982 it should have been clear to clinicians that AIDS was a disorder transmissible by blood and blood products and that it was "the only clinical interpretation of the data that was available."

Published on:

A paper titled "Acquired Immunodeficiency Syndrome: Infection and Neoplasia in Homosexual Men and Intravenous Drug Addicts" was presented to the Second International Symposium on Infections in the Immunocompromised Host. The paper named blood as a potential vehicle of AIDS infection.

Published on:

In his letter to The Lancet, Dr Jones recommended "continued, careful surveillance of the severely affected haemophilic population." Yet it made no mention of a virus as an infective agent.

Published on:

In a letter to the Press Council, Dr Jones lodged a formal complaint about an article on The Mail on Sunday with the headline "Hospitals using killer blood". He argued that there was no proof that a virus was the cause of AIDS nor that it was imported from the US.

Published on:

In a letter to colleagues, Dr Jones stressed that the link between AIDS and Haemophilia is weak and warned against withdrawing Factor 8 treatment.

Published on:

Dr Jones rejected the need for a change in treatment policy partly because the emergence of HIV/AIDS "in a few haemophiliacs does not necessarily reflect the tip of an iceberg".

Published on:

After 1983, Dr Jones would have children from around the age of six transferred from cryoprecipitate to concentrate for home therapy.

Published on:

Dr Frank Boulton stated to the Penrose Inquiry "Peter Jones and many like him were reluctant to... go back ten years or so to the style of treatments usually only cryoprecipitate or small pooled products which would reduce the dosage that children could get and return them to a risk of getting permanent joint damage from their early years".

Published on:

Dr Boulton felt that Dr Jones was "still being somewhat less than cautious" with regard to his attitude towards the risk of AIDS.

Published on:

Commercial concentrates continued to be the mainstay of treatment at the Newcastle Haemophilia Centre in 1983.

Published on:

Commercial concentrates continued to be the mainstay of treatment at the Newcastle Haemophilia Centre in 1984.

Published on: